To appraise the clinical and cost effectiveness of brentuximab vedotin within its marketing authorisation for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma.
 
Status In progress
Process STA pre-2018
ID number 1190

Provisional Schedule

Committee meeting: 1 27 November 2018
Expected publication 22 May 2019

Project Team

Project lead Stephanie Callaghan

Email enquiries

Consultees

Companies sponsors Takeda (brentuximab vedotin)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Bloodwise
  Lymphoma Action
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute

Timeline

Key events during the development of the guidance:

Date Update
06 December 2017 In progress, In progress
05 December 2017 This appraisal is to be rescheduled to allow the company (Takeda) additional time to incorporate important information into their submission, including a new commercial arrangement. A new deadline for submissions (previously 7 December 2017) and committee date will be confirmed in due course.
12 October 2017 Invitation to participate
24 July 2017 - 21 August 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
26 July 2017 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance